IRUXOL OINT; collagenase, dermatological agents .
ACTIVE-INGREDIENT OF IRUXOL OINT
Each gram of ointment contains 0.6 units of clostridiopeptidase A in a lipophilic anhydrous ointment base.
INDICATION OF IRUXOL OINT
Iruxol is indicated for the enzymatic debridement of necrotizing wounds, including leg and decibital ulcers. In ulcerations & necroses, such as leg ulcer, decumbitus, gangrene of the extremities, especially diabetic gangrene, frostbite: in poorly healing wounds i.e. in wounds after operations, radiotherapy, accidents. In all type of burns & before skin grafting.
DOSAGE OF IRUXOL OINT
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
For topical administration. A layer of approximately 2 mm of ointment should be applied to the dressing or directly to the slightly moistened area to be treated once daily. Close contact to the wound surface should be assured. Occasionally, twice daily use may be required. It is unnecessary to apply too great an amount of the product to the wound. With this, the cleaning process is not improved. In general it will suffice to change the dressing once daily. An increase of activity may possibly be obtained by applying the ointment twice daily. The treatment of varicose ulcers with Iruxol ointment will be usefully supplemented by a pressure bandage and in arterial circulatory disorders, ulcers of diabetic or neurologic etiology, by appropriate drug treatment. To ensure successul enzymatic wound treatment with Iruxol ointment, sufficient moisture must be present in the wound area during therapy. In dry wounds, the wound base must therefore be moistened with physiological saline (0.9% NaCl) or other solutions which are well tolerated by the tissue ( e.g. glucose ). Dry and hard crusts should first be softened by applying a moist dressing. Treatment with Iruxol should be discontinued when the whole surface of the wound is clean. Whenever infection is present, an appropriate antibiotic treatment should be considered. Chloraphenicol, neomycin, framcetin, bacitracin, gentamicin, polymyxin B and macrolides, e.g. erythromycin, have been shown to be compatible with Iruxol. As is common clinical practice, the wound edges and healthy skin should be protected in order to avoid irritation.
OVER-DOSAGE OF IRUXOL OINT
In case of swallen by mouth, inavertent intake of the drug is unlikely, but if it occurs, it should be removed from the stomach ( vomiting or gastrolavage, if required ).
CONTRA-INDICATION OF IRUXOL OINT
Iruxol is contra-indicated in patients hypersensitive to any of the ingredients.
STORAGE OF IRUXOL OINT
Store at temperature not exceeding 25 °C.
PACK OF IRUXOL OINT
Aluminium tubes contains 15 g of ointment.
IRUXOL OINT MANUFACTURED BY
Kahira pharm. & chem. Ind. Co. Under licence of Abbott Laboratories Germany For Abbott Egypt.